Literature DB >> 11748232

HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter.

Michal Stros1, Toshinori Ozaki, Alena Bacikova, Hajime Kageyama, Akira Nakagawara.   

Abstract

The recently cloned gene p73 is a close homologue of p53, which is a crucial tumor suppressor gene for preventing the malignant transformation of cells by inducing cell cycle arrest and apoptosis. Previous reports have shown that architectural DNA-bending/looping chromosomal proteins HMGB1 and HMGB2 (formerly known as HMG1 and HMG2), which function in a number of biological processes including transcription and DNA repair, interact in vitro with p53 and stimulate p53 binding to DNA containing p53 consensus sites. Here, we report that HMGB1 physically interacts with two splicing variants of p73, alpha and beta (pull-down assay), and enhances binding of p73 to specific cognate DNA sites (gel-shift assay). Both HMG box domains of HMGB1, A and B, interact with p73alpha. Association of HMGB1 with p73, like the demonstrated ability of HMGB1 to stimulate p73 binding to different p53-responsive elements, requires the oligomerization region and/or region between DNA-binding domain and oligomerization domain of p73 (residues 312-381). Transient transfections revealed that ectopically expressed or endogenous HMGB1 and HMGB2 (antisense strategy) significantly inhibit in vivo both p73alpha/beta- and p53-dependent transactivation from the Bax gene promoter (and much less from Mdm2 and p21(waf1) promoters) in p53-deficient SAOS-2 cells. In contrast, HMGB1 and HGMB2 stimulate p73- or p53-dependent transactivation in p53-deficient H1299 cells, irrespective of the promoter used. Our results suggest that ubiquitously expressed HMGB1 and HMGB2 have potential to cell- and promoter-specifically down- or up-regulate in vivo transcriptional activity of different members of the p53 family. A possible mechanism of HMGB1-mediated modulation of p73- and p53-dependent transactivation is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748232     DOI: 10.1074/jbc.M110233200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

1.  NMR structure of the KaiC-interacting C-terminal domain of KaiA, a circadian clock protein: implications for KaiA-KaiC interaction.

Authors:  Ioannis Vakonakis; Jingchuan Sun; Tianfu Wu; Andreas Holzenburg; Susan S Golden; Andy C LiWang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-28       Impact factor: 11.205

2.  HMGB1 gene knockout in mouse embryonic fibroblasts results in reduced telomerase activity and telomere dysfunction.

Authors:  Eva Polanská; Zuzana Dobšáková; Martina Dvořáčková; Jiří Fajkus; Michal Štros
Journal:  Chromosoma       Date:  2012-04-28       Impact factor: 4.316

Review 3.  Ménage à Trois in stress: DAMPs, redox and autophagy.

Authors:  Guanqiao Li; Daolin Tang; Michael T Lotze
Journal:  Semin Cancer Biol       Date:  2013-08-28       Impact factor: 15.707

4.  Differentially Expressed mRNA Targets of Differentially Expressed miRNAs Predict Changes in the TP53 Axis and Carcinogenesis-Related Pathways in Human Keratinocytes Chronically Exposed to Arsenic.

Authors:  Laila Al-Eryani; Sabine Waigel; Ashish Tyagi; Jana Peremarti; Samantha F Jenkins; Chendil Damodaran; J C States
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

5.  P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3.

Authors:  Abdessamad Zerrouqi; Beata Pyrzynska; Maria Febbraio; Daniel J Brat; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

6.  High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell.

Authors:  Young-Joo Shin; Mi-Sook Kim; Moon-Sun Kim; Joonseok Lee; Miae Kang; Jae-Hoon Jeong
Journal:  Cancer Biol Ther       Date:  2012-12-19       Impact factor: 4.742

7.  High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs.

Authors:  Natalia Krynetskaia; Hongbo Xie; Slobodan Vucetic; Zoran Obradovic; Evgeny Krynetskiy
Journal:  Mol Pharmacol       Date:  2007-10-19       Impact factor: 4.436

8.  Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1.

Authors:  Marie-Thérèse Melki; Héla Saïdi; Alexandre Dufour; Jean-Christophe Olivo-Marin; Marie-Lise Gougeon
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

9.  Downregulation of HMGB1 by miR-34a is sufficient to suppress proliferation, migration and invasion of human cervical and colorectal cancer cells.

Authors:  Karthik Subramanian Chandrasekaran; Anusha Sathyanarayanan; Devarajan Karunagaran
Journal:  Tumour Biol       Date:  2016-07-25

10.  Co-treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells.

Authors:  K Fujii; Y Luo; T Sasahira; A Denda; H Ohmori; H Kuniyasu
Journal:  Cell Prolif       Date:  2009-07-06       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.